• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

局部进展期胰腺腺癌的多学科综合治疗:生物学是关键。

Multidisciplinary management of locally advanced pancreatic adenocarcinoma: Biology is King.

机构信息

Department of Surgical Oncology, City of Hope National Medical Center, Duarte, California, USA.

Department of Radiation Oncology, City of Hope National Medical Center, Duarte, California, USA.

出版信息

J Surg Oncol. 2021 May;123(6):1395-1404. doi: 10.1002/jso.26415.

DOI:10.1002/jso.26415
PMID:33831247
Abstract

The annual incidence of pancreatic cancer is nearly 50,000 patients. The 5-year overall survival is only 9%, and there remains a great need for better therapy. A subset of these patients presents with locally advanced disease. Multidisciplinary therapy has evolved to include some combination of systemic chemotherapy, locoregional radiation, and surgery in select patients with excellent biology. This review will address the thoughtful evidence-based and individualized approach to these patients.

摘要

每年胰腺癌的发病率接近 5 万例。患者的 5 年总生存率仅为 9%,因此仍然迫切需要更好的治疗方法。这些患者中有一部分表现为局部晚期疾病。多学科治疗已经发展到包括某些组合的全身化疗、局部区域放疗以及在生物学表现良好的患者中进行的手术。这篇综述将讨论对这些患者进行的基于深思熟虑的循证和个体化方法。

相似文献

1
Multidisciplinary management of locally advanced pancreatic adenocarcinoma: Biology is King.局部进展期胰腺腺癌的多学科综合治疗:生物学是关键。
J Surg Oncol. 2021 May;123(6):1395-1404. doi: 10.1002/jso.26415.
2
Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma.新辅助治疗用于胰腺导管腺癌的趋势。
J Surg Oncol. 2021 May;123(6):1432-1440. doi: 10.1002/jso.26384.
3
Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX.吉西他滨/白蛋白紫杉醇解救治疗 FOLFIRINOX 早期失败后局部晚期或边缘可切除胰腺腺癌患者的获益。
Pancreas. 2019 Jul;48(6):837-843. doi: 10.1097/MPA.0000000000001345.
4
Treatment landscape of metastatic pancreatic cancer.转移性胰腺癌的治疗现状。
Cancer Treat Rev. 2021 May;96:102180. doi: 10.1016/j.ctrv.2021.102180. Epub 2021 Mar 17.
5
A review of response in neoadjuvant therapy for exocrine pancreatic cancer.胰腺外分泌癌新辅助治疗的疗效综述
J Surg Oncol. 2021 May;123(6):1449-1459. doi: 10.1002/jso.26369.
6
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Pancreatic Adenocarcinoma.新加坡癌症网络(SCAN)胰腺癌全身治疗指南。
Ann Acad Med Singap. 2015 Oct;44(10):388-96.
7
Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.原发性化疗治疗交界可切除和局部进展期胰腺导管腺癌的结果。
JAMA Surg. 2019 Oct 1;154(10):932-942. doi: 10.1001/jamasurg.2019.2277.
8
Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection.新辅助改良 FOLFIRINOX 对比 nab-紫杉醇联合吉西他滨治疗手术可切除或局部进展期胰腺癌患者。
Cancer Med. 2020 Jul;9(13):4711-4723. doi: 10.1002/cam4.3075. Epub 2020 May 16.
9
R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial.放化疗后 R0 切除术可改善无法手术的原发性胰腺癌患者的生存。德国随机对照 CONKO-007±试验的中期结果。
Strahlenther Onkol. 2021 Jan;197(1):8-18. doi: 10.1007/s00066-020-01680-2. Epub 2020 Sep 10.
10
FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.FOLFIRINOX 对比吉西他滨/白蛋白紫杉醇用于可切除和交界可切除胰头腺癌的新辅助治疗。
Ann Surg Oncol. 2018 Jul;25(7):1896-1903. doi: 10.1245/s10434-018-6512-8. Epub 2018 May 14.

引用本文的文献

1
Impact of a non-therapeutic laparotomy in patients with locally advanced pancreatic cancer treated with induction (m)FOLFIRINOX: Trans-Atlantic Pancreatic Surgery (TAPS) Consortium study.诱导(m)FOLFIRINOX 治疗局部晚期胰腺癌患者中非治疗性剖腹术的影响:跨大西洋胰腺外科(TAPS)联盟研究。
Br J Surg. 2024 Mar 2;111(3). doi: 10.1093/bjs/znae033.
2
A pancreatic adenocarcinoma mimicking hepatoid carcinoma of uncertain histogenesis: A case report and literature review.一例组织发生不明的类似肝样癌的胰腺腺癌:病例报告及文献复习
Oncol Lett. 2023 Aug 28;26(4):442. doi: 10.3892/ol.2023.14029. eCollection 2023 Oct.